Schonfeld Strategic Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$260K	Buy	+84,556	New	+$327K	﹤0.01%	1638
2025 Q3	–	Sell	-21,371	Closed	-$108K	–	2525
2025 Q2	$108K	Buy	+21,371	New	+$105K	﹤0.01%	1835
2025 Q1	–	Sell	-54,511	Closed	-$368K	–	2461
2024 Q4	$368K	Buy	+54,511	New	+$366K	﹤0.01%	1528
2023 Q1	–	Sell	-81,204	Closed	-$626K	–	2577
2022 Q4	$626K	Sell	81,204 -35,807	-31%	-$351K	0.01%	1404
2022 Q3	$1.24M	Sell	117,011 -55,184	-32%	-$559K	0.01%	1132
2022 Q2	$1.4M	Buy	172,195 +81,395	+90%	+$545K	0.01%	867
2022 Q1	$650K	Buy	+90,800	New	+$965K	0.01%	1218

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Schonfeld Strategic Advisors's RXRX Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 84,556 shares worth $260K. The stake represents ﹤0.01% of the portfolio and ranks #1638 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in RXRX as recently as Q2 2025.

Schonfeld Strategic Advisors first reported a position in RXRX in Q1 2022 and has held it in 7 quarters since. The position peaked at $1.4M in Q2 2022. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Schonfeld Strategic Advisors held 84,556 shares of Recursion Pharmaceuticals worth $260K as of Q1 2026.
Recursion Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1638 holding.
Schonfeld Strategic Advisors first reported a position in Recursion Pharmaceuticals in Q1 2022 and has held it in 7 quarters since.
Schonfeld Strategic Advisors's Recursion Pharmaceuticals position peaked at $1.4M in Q2 2022.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.